Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 513 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Estrogen Receptor-negative Breast Cancer Clear all

Conditions: Breast Cancer
Interventions: gemcitabine/carboplatin, iniparib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 18
States / cities: Birmingham, Alabama • Denver, Colorado • Torrington, Connecticut + 15 more

Conditions: Advanced Solid Tumors, Advanced Breast Cancer
Interventions: ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant; Drug
Lead sponsor: Ensem Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more

Conditions: Breast Cancer
Interventions: gemcitabine/carboplatin, Iniparib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 519 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 102
States / cities: Birmingham, Alabama • Sedona, Arizona • Jonesboro, Arkansas + 98 more

Conditions: Estrogen Receptor Positive Breast Cancer
Interventions: hydroxychloroquine; Drug
Lead sponsor: Western Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Goodyear, Arizona

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Capecitabine, Carboplatin, Cisplatin; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2031
U.S. locations: 1023
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more

Conditions: Breast Cancer
Interventions: Fulvestrant with Enzalutamide; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Aurora, Colorado • Lone Tree, Colorado • Germantown, Tennessee

Conditions: Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions: SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine, SOC, Antiandrogen; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 6
States / cities: New Haven, Connecticut • Baltimore, Maryland • Rochester, Minnesota + 3 more

Conditions: Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Aromatase Inhibitor, Laboratory Biomarker Analysis, Pharmacokinetic Study, Questionnaire Administration, Ribociclib; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 70 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 9
States / cities: Corona, California • Duarte, California • Lancaster, California + 6 more

Conditions: Triple Negative Breast Cancer, Breast Neoplasms
Interventions: P10s-PADRE with MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide, Paclitaxel; Biological · Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Little Rock, Arkansas

Conditions: Breast Cancer
Interventions: Letrozole, Placebo, Taselisib; Drug · Other
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: Santa Ana, California • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more

Conditions: Breast Neoplasms
Interventions: PD-0332991, Letrozole, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 136
States / cities: Bellflower, California • Beverly Hills, California • Fullerton, California + 83 more

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 13
States / cities: Duarte, California • Grand Rapids, Michigan • Long Island City, New York + 7 more

Conditions: Breast Cancer
Interventions: Metformin, Placebo, Questionnaires, Sensory and Fine-Motor Tests; Drug · Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 74 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Prostate Carcinoma, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm, Triple-Negative Breast Carcinoma
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Veliparib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 4 more

Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
Interventions: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 42
States / cities: Gilbert, Arizona • Phoenix, Arizona • Springdale, Arkansas + 31 more

Conditions: Neoplasms, Breast
Interventions: lapatinib, bevacizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 9
States / cities: Tucson, Arizona • San Francisco, California • Hollywood, Florida + 6 more

Conditions: Breast Cancer
Interventions: cyclophosphamide, doxorubicin hydrochloride, paclitaxel, fluorescence in situ hybridization, immunohistochemistry staining method; Drug · Genetic · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer Metastatic
Interventions: Amcenestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 14
States / cities: Birmingham, Alabama • Bakersfield, California • Santa Monica, California + 11 more

Conditions: Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast
Interventions: Mammaglobin-A DNA Vaccine, Optional biopsy; Biological · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Interventions: PDR001, ACZ885, CJM112, TMT212, EGF816; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Seattle, Washington • Tacoma, Washington

Conditions: Breast Cancer
Interventions: Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 170
States / cities: Daphne, Alabama • Chandler, Arizona • Gilbert, Arizona + 134 more

Conditions: Breast Cancer
Interventions: Imipramine; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 71 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Cancer
Interventions: Fulvestrant, Ganetespib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: Boston, Massachusetts • Concord, New Hampshire • Chapel Hill, North Carolina

Search by objective public record fields.

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

Vaccination of Triple Negative Breast Cancer Patients

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Imipramine on ER+ve and Triple Negative Breast Cancer

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer